Mammographic Density Change With Estrogen and Progestin Therapy and Breast Cancer Risk by Byrne, C. et al.
ARTICLE
Mammographic Density Change With Estrogen and
Progestin Therapy and Breast Cancer Risk
Celia Byrne, Giske Ursin, Christopher F. Martin, Jennifer D. Peck,
Elodia B. Cole, Donglin Zeng, Eunhee Kim, Martin D. Yaffe, Norman F. Boyd,
Gerardo Heiss, Anne McTiernan, Rowan T. Chlebowski, Dorothy S. Lane,
JoAnn E. Manson, Jean Wactawski-Wende, Etta D. Pisano
Affiliations of authors: Uniformed Services University of the Health Sciences, Bethesda, MD (CB); Cancer Registry of Norway, Institute of Population Based Cancer
Research, Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway and Department of Preventive Medicine, University of
Southern California, Los Angeles, CA, US (GU); University of North Carolina at Chapel Hill, Chapel Hill, NC (CFM, DZ, GH); The University of Oklahoma Health Sciences
Center, Oklahoma City, OK (JDP); Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA (EBC, EDP); National Institutes of Health, Bethesda, MD
(EK); Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada (MDY); Ontario Cancer Institute, Toronto, Ontario, Canada (NFB); Fred Hutchinson Cancer Research
Center, Seattle, WA (AM); Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA (RTC); Stony Brook School of Medicine, Stony Brook,
NY (DSL); Brigham and Women’s Hospital, Harvard Medical School, Boston, MA (JEM); University at Buffalo, State University of New York, Buffalo, NY (JWW)
Correspondence to: Celia Byrne, PhD, Uniformed Services University, 4301 Jones Bridge Road A-1039F, Bethesda, MD 20814 (e-mail: celia.byrne@usuhs.edu).
Abstract
Background: Estrogen plus progestin therapy increases both mammographic density and breast cancer incidence. Whether
mammographic density change associated with estrogen plus progestin initiation predicts breast cancer risk is unknown.
Methods: We conducted an ancillary nested case-control study within the Women’s Health Initiative trial that randomly as-
signed postmenopausal women to daily conjugated equine estrogen 0.625 mg plus medroxyprogesterone acetate 2.5 mg or
placebo. Mammographic density was assessed from mammograms taken prior to and one year after random assignment for
174 women who later developed breast cancer (cases) and 733 healthy women (controls). Logistic regression analyses in-
cluded adjustment for confounders and baseline mammographic density when appropriate.
Results: Among women in the estrogen plus progestin arm (97 cases/378 controls), each 1% positive change in percent
mammographic density increased breast cancer risk 3% (odds ratio [OR] ¼ 1.03, 95% confidence interval [CI] ¼ 1.01 to 1.06). For
women in the highest quintile of mammographic density change (>19.3% increase), breast cancer risk increased 3.6-fold (95%
CI¼1.52 to 8.56). The effect of estrogen plus progestin use on breast cancer risk (OR¼1.28, 95% CI¼0.90 to 1.82) was
eliminated in this study, after adjusting for change in mammographic density (OR¼1.00, 95% CI¼0.66 to 1.51).
Conclusions: We found the one-year change in mammographic density after estrogen plus progestin initiation predicted sub-
sequent increase in breast cancer risk. All of the increased risk from estrogen plus progestin use was mediated through mam-
mographic density change. Doctors should evaluate changes in mammographic density with women who initiate estrogen
plus progestin therapy and discuss the breast cancer risk implications.
After 5.6 years (mean) of intervention, the Women’s Health
Initiative (WHI) randomized clinical trial identified net harm for
estrogen plus progestin users including 24% increased breast
cancer incidence (1,2). Subsequently, estrogen plus progestin
use declined in the United States and elsewhere (3–7), followed
by lower invasive breast cancer incidence in most Western
countries, largely attributed to reduced estrogen plus progestin
usage (6–9). Clinical trials confirmed the observational studies’
reports that percent mammographic density, the proportion of
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increased with estrogen plus progestin use (13–15).
Mammographic density increased more with combined estro-
gen plus progestin use than estrogens alone (13,14,16–18). After
one year, estrogen plus progestin use increased mammographic
density by 6.9% (95% confidence interval [CI] ¼ 5.3% to 8.5%)
compared with placebo in the WHI (15).
Mammographic density strongly predicted breast cancer risk
in numerous studies (10–12,19). Risk increased four- to sixfold
comparing women with high mammographic density with
women with low mammographic breast density (10–12). Until
now, only insufficient indirect evidence has suggested that
mammographic density change, occurring with estrogen plus
progestin initiation, predict increased breast cancer risk. The
extent that mammographic density change following estrogen
plus progestin initiation increased breast cancer incidence re-
mains unclear. We conducted an ancillary nested case-control
study within the WHI randomized, placebo-controlled clinical




All study sites’ institutional review boards approved this ancil-
lary study and all participants provided written informed
consent.
Between 1993 and 1998, the WHI randomly assigned 16 608
postmenopausal women without prior hysterectomy to estro-
gen plus progestin (0.625 mg daily conjugated equine estrogen
and 2.5 mg medroxyprogesterone acetatein, single tablet;
Prempro, Wyeth Ayerst, Philadelphia, PA) or an identically ap-
pearing placebo (20). Eligibility criteria, recruitment, and imple-
mentation details were published (20). In brief, eligible
postmenopausal women age 50 to 79 years had no prior hyster-
ectomy or breast cancer and estimated survival of three or more
years (20). Prior use of menopausal hormones required three-
month washout before baseline. WHI participation required
baseline mammogram and clinical breast exam without sugges-
tion of cancer. Study continuation required annual mammo-
gram and breast exam without suspicions of cancer. Centrally
trained local adjudicators evaluated pathology reports and
medical records for all self-reported breast cancers. WHI
Clinical Coordinating Center coders performed final adjudica-
tion blinded to random assignment status. Follow-up for clinical
outcomes among consenting women lasted 7.9 years (mean)
(21). Compliance to the treatment protocol was greater than
90% in both arms of the WHI study through year 1 (1,2).
Compliance decreased throughout the WHI, so by the end of
follow-up, 42% assigned estrogen plus progestin and 38% as-
signed placebo stopped the study medications for at least some
time (1,2). Furthermore, 6.2% of women assigned estrogen plus
progestin and 10.7% assigned placebo arm stopped the trial
medication and obtained hormones outside of the WHI (1,2).
This ancillary study sought baseline and one-year follow-up
mammograms for women who subsequently developed inva-
sive breast cancer (cases) and a stratified (stratum based on
age—within two years, clinical center, and race/ethnicity) ran-
dom sample of three unaffected women (controls) per case. In
total, 399 breast cancer cases were identified (n ¼ 224 assigned
estrogen plus progestin and n ¼ 175 assigned placebos), and
1197 cancer-free controls were identified (n ¼ 618 assigned es-
trogen plus progestin and n ¼ 579 assigned placebos). Controls
were free of breast cancer when the matched case was diag-
nosed. We contacted and consented eligible participants re-
questing mammograms for this ancillary study. Procedures to
obtain the relevant mammograms followed those from an ear-
lier WHI mammography study (15). Thirty-six of the 40 WHI
clinical centers participated, and 61% of the mammograms re-
quested were obtained. A smaller percentage of mammograms
were obtained for cases (43.6%) than for controls (61.2%); how-
ever, no substantial difference by treatment arm for either cases
(43.3% for estrogen plus progestin and 44% for placebo) or for
controls (61.2% for estrogen plus progestin and 61.3% for pla-
cebo) existed. The major reasons for recovery failure included
consent not obtained (42%), films no longer available (33%), in-
complete image sets provided (13%), patient deceased (8%), and
patient ineligible (4%).
All baseline and follow-up film mammograms sent to the
University of North Carolina were digitized using a Kodak
Lumisys 85 laser-scanning digitizer (Kodak, Rochester, NY).
Standard data averaging methods reduced the image, digitized
at 50 micron/pixel spatial resolution and 12-bit depth, to 675 
925 pixels. Mammographic density assessment used cranio-
caudal views from the contralateral, cancer-free breast side for
all cases and a random side for the controls. All batches in-
cluded approximately 5% repeated images for within- and be-
tween-batch reproducibility assessments. All mammographic
images randomly sorted for a given participant were read
within the same batch (22). Mammograms for 973 participants
were obtained and digitized. However, 66 participants had no
baseline mammograms, leaving 907 participants with complete
baseline and follow-up mammogram sets, comprising 174
breast cancer cases (97 from the estrogen plus progestin arm
and 77 from the placebo arm) and 733 controls (378 from the es-
trogen plus progestin arm and 355 from the placebo arm).
Assessment of Mammographic Density
Using two different but comparable validated interactive soft-
ware tools, four readers (CB, GU, CM, and JP), blinded to partici-
pant information, viewed all mammograms on high-resolution
monitors for breast density assessment. Three readers (CB, CM,
and JP) used Cumulus software developed at the University of
Toronto (23,24). The fourth reader (GU) used Madena software
developed at the University of Southern California (25). Both
software tools calculated the number of pixels defined by the
reader as dense within the breast and the number of pixels in
the total breast area. The ratio of dense pixels to total pixel in
the breast, expressed as a percentage, determined percent
mammographic density.
Statistical Analyses
We used SAS 9.0 (Cary, NC) for data analyses and calculations of
95% confidence intervals (CIs) and P values based on the Wald
test. All statistical tests were two-sided, and results were con-
sidered statistically significant at a P value of less than .05.
Univariate and bivariate analyses presented the primary vari-
able distributions. A woman’s original randomized treatment
arm (estrogen plus progestin or placebo) defined exposure, re-
gardless of subsequent compliance. Initial logistic regression
models evaluated the percent density and percent density
change effects on breast cancer risk separately by reader.
Although dense area values differed by reader, the comparison
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(Pearson correlations of R ¼ 0.90–0.97), and breast area assess-
ment also correlated highly between readers (Pearson correla-
tions of R ¼ 0.94–0.99). Because univariate odds ratios (ORs) for
breast cancer associated with mammographic density across
the four readers were quite consistent, subsequent analyses
used the mean mammographic density of the four readers
(Table 1). The continuous variable of mammographic density
compared a 1% difference in baseline mammographic density
percent or 1% change in mammographic density percent.
Analytic Model
Because earlier WHI analyses established that estrogen plus
progestin treatment increased breast cancer risk, our initial
analyses determined if mammographic density change was as-
sociated with increased breast cancer risk. To adjust for poten-
tial confounders, logistic regression models included breast
cancer risk factors associated with mammographic density
change. The initial model contained center, age at baseline
(continuous), ethnicity (non-Hispanic white, African American,
and other) baseline BMI (continuous), BMI change (continuous),
age at first birth (<20, 20–24, 25–29, 30–34, and 35þ years/miss-
ing), parity (0, 1, 2, 3, missing), length of follow-up (continuous),
personal history of menopausal hormone therapy use (never,
previous, current user prior to three-month washout), age at
last birth (<20, 20–24, 25–29, 30þ years, and missing), time since
menopause (continuous), first-degree family history of breast
cancer (yes, no, and missing), and alcohol consumption at base-
line (yes, no, and missing). Individually, factors least associated
with cancer risk were considered for removal. Retained factors
changed the beta estimate in the final model by 10% or more.
The final model included age, baseline BMI, center, age at first
birth, and parity. We evaluated effects of baseline mammo-
graphic density and mammographic density change stratified
by treatment group, as well as potential interactions between
these measures. Separate logistic regression models adjusted
for covariates included interaction terms for baseline density
and treatment arm, baseline density and mammographic den-
sity change, and treatment arm and mammographic density
change. Additional analyses of quintiles of mammographic den-
sity change evaluated potential nonlinear effects.
Mammographic density change quintile cut-points were 0.6%,
4.6%, 10.7%, and 19.3% in the estrogen plus progestin group, and
-2.8%, -0.51%, 0.40%, and 2.2% in the placebo group. Separate lo-
gistic regression models evaluated mammographic density
change associations across three levels of baseline mammo-
graphic density (<10%, 10%–25%, and >25%). We calculated the
attributable risk for increased mammographic density after es-
trogen plus progestin initiation with 95% confidence intervals
using bootstrap methods.
To evaluate how well this study represented the WHI clinical
trial cohort, we determined estrogen plus progestin effects on
breast cancer risk in this mammography substudy with logistic
regression. We evaluated if the odds ratio differed after control-
ling for mammographic density change, hypothesizing that a
reduced or null odds ratio for breast cancer associated with es-
trogen plus progestin would indicate that mammographic den-
sity change explained the estrogen plus progestin influence on
breast cancer risk. We conducted mediation analyses of the es-
trogen plus progestin total effect on breast cancer risk, with
mammographic density change as the mediating variable, to
assess the proportion-mediated measure (indirect effect/total
effect) (26).
Results
Women assigned placebos exhibited minimal mammographic
density change over one year (mean change ¼ -0.05%) (Figure 1).
In contrast, those assigned estrogen plus progestin had a larger
and a broad distribution of mammographic density change
Table 1. Baseline percent mammographic density and change in percent mammographic density and univariate odds ratios for the association
with breast cancer risk by case status and treatment arm for each of four readers and the average of the four readers
Comparisons/subgroups
Reader
Average of all readers1 2 3 4
Reliability coefficient 0.876 0.899 0.938 0.965
Baseline percent Mammographic density
Placebo (n¼ 432)
Controls (n¼ 355) Mean (SD) 20.42 (18.50) 9.50 (10.60) 12.84 (15.38) 14.66 (17.00) 14.36 (14.65)
Cases (n¼ 77) Mean (SD) 17.28 (13.91) 8.45 (8.99) 10.07 (11.41) 13.21 (14.50) 12.25 (11.60)
OR* (95% CI) 0.99 (0.98 to 1.00) 0.99 (0.97 to 1.02) 0.99 (0.97 to 1.01) 1.00 (0.98 to 1.01) 0.99 (0.97 to 1.01)
Estrogen plus progestin (n¼ 475)
Controls (n¼ 378) Mean (SD) 18.84 (15.88) 9.96 (10.29) 11.38 (13.02) 12.66 (14.18) 13.55 (13.01)
Cases (n¼ 97) Mean (SD) 22.20 (18.62) 12.96 (12.02) 15.89 (16.93) 14.59 (16.59) 17.54 (16/09)
OR* (95% CI) 1.01 (0.999 to 1.03) 1.02 (1.01 to 1.04) 1.02 (1.01 to 1.04) 1.02 (1.01 to 1.03) 1.02 (1.00 to 1.04)
Change in percent Mammographic density
Placebo (n¼ 432)
Controls (n¼ 355) Mean (SD) to 0.68 (9.85) to 0.06 (3.40) to 0.22 (5.44) 0.08 (4.36) to 0.22 (4.49)
Cases (n¼ 77) Mean (SD) 0.98 (10.45) to 0.12 (2.92) 0.74 (5.81) 1.32 (5.53) 0.73 (5.03)
OR* (95% CI) 1.02 (0.99 to 1.04) 0.99 (0.92 to 1.07) 1.03 (0.99 to 1.08) 1.06 (1.00 to 1.11) 1.05 (0.99 to 1.10)
Estrogen plus progestin (n¼ 475)
Controls (n¼ 378) Mean (SD) 12.66 (14.18) 4.45 (6.53) 4.17 (7.84) 10.57 (12.71) 9.49 (10.50)
Cases (n¼ 97) Mean (SD) 14.59 (16.59) 10.29 (12.64) 10.67 (14.85) 13.18 (15.82) 10.65 (12.63)
OR* (95% CI) 1.01 (0.99 to 1.02) 0.99 (0.96 to 1.03) 1.00 (0.99 to 1.02) 1.01 (1.00 to 1.03) 1.01 0.99 to 1.03
*Note that these are univariate results and the odds ratios for breast cancer correspond with having 1% more mammographic density at baseline and a 1% mean
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(mean change ¼ 9.7%) (Figure 2). Of the 432 placebo-assigned
women, 202 (46.8%) increased in mammographic density while
230 (53.2%) decreased. In contrast, of 475 estrogen plus proges-
tin–assigned women, 399 (84.0%) increased in mammographic
density while only 76 (16.0%) decreased. After adjusting for co-
variates including baseline density, the difference in mean
change in mammographic density between the placebo (-0.65%,
95% CI ¼ -1.86 to 0.55) and the estrogen plus progestin (9.49%,
95% CI¼ 8.25 to 10.72) treatment arms was statistically signifi-
cant (P < .001).
Overall, after adjustment, each 1% difference in baseline
mammographic density increased breast cancer risk by 1%
(OR¼ 1.01, 95% CI¼ 1.00 to 1.02). Additional adjustment for
treatment arm did not change this association. In treatment-
stratified analyses, baseline mammographic density did not in-
crease breast cancer risk among women assigned placebos, but
breast cancer risk increased 3% among women assigned
estrogen plus progestin (OR ¼ 1.03, 95% CI¼ 1.01 to 1.05) with
each 1% baseline density difference (Table 2). The interaction
between baseline mammographic density with treatment
(b ¼ 0.032, P ¼ .02) was statistically significant. Controlling
for baseline mammographic density (Table 2), a 1% change in
mammographic density increased breast cancer risk 4%, but not
statistically significantly, in women assigned placebos. In con-
trast, the increased breast cancer risk in women assigned estro-
gen plus progestin of 3% (OR¼ 1.03, 95% CI¼ 1.01 to 1.06) with a










Change in mammographic density
Figure 1. Distribution of change in mammographic density from baseline to at least one year after random assignment within participants from the placebo arm of the
Women’s Health Initiative. The mean change in percent mammographic density declined by 0.05%, with a median change in mammographic density of 0.0% and a
standard deviation of 6.36.









Change in mammographic density
Figure 2. Distribution of change in mammographic density from baseline to at least one year after random assignment within participants from the estrogen plus pro-
gestin arm of the Women’s Health Initiative. The mean change in percent mammographic density increased by 9.73%, with a median change in mammographic den-
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1% change in mammographic density was statistically signifi-
cant. Controlling for baseline mammographic density, the inter-
action between mammographic density change and treatment
group was not statistically significant (P ¼ .34). Table 3 shows
the mammographic density change effects within strata of
baseline density. In the placebo and the estrogen plus progestin
arms, having more than 25% density at baseline reduced the
magnitude of the association between mammographic density
change and breast cancer risk (Table 3). Controlling for treat-
ment arm and other covariates, baseline mammographic den-
sity negatively interacted with mammographic density change
(b ¼ -0.0013, P ¼ .03).
In addition to linear effects, we evaluated quintiles of mam-
mographic density change based on the distributions within
each randomized arm (Table 4). The cut-points for the upper
quintile of mammographic density change were 2.2% or greater
for women using placebo and 19.3% or greater for women using
estrogen plus progestin. In the placebo arm, the increase in
breast cancer risk was not statistically significant (OR¼ 1.20,
95% CI¼ 0.48 to 2.97) comparing the highest to the lowest quin-
tile of mammographic density change. In contrast, there was a
statistically significant 3.6-fold increased risk in breast cancer
in the estrogen plus progestin arm comparing the highest with
the lowest quintile of mammographic density change
(OR¼ 3.61, 95% CI¼ 1.52 to 8.56).
Women in the estrogen plus progestin arm had increased
breast cancer risk compared with those in the placebo arm
(OR¼ 1.28, 95% CI¼ 0.90 to 1.82), a finding comparable with the
overall randomized clinical trial where a 24% increase was re-
ported (hazard ratio [HR] ¼1.24, 95% CI¼ 1.01 to 1.54) (2,27).
Including mammographic density change in the analytic model,
no residual effect of estrogen plus progestin on breast cancer
risk remained (OR ¼ 1.00, 95% CI¼ 0.66 to 1.51). In an unadjusted
mediation model, 97.4% of the estrogen plus progestin use ef-
fect was mediated through density change, while in a model ad-
justed for covariates and interaction, 100% of the estrogen plus
progestin effect was mediated through density change. To de-
termine if estrogen plus progestin only increased breast cancer
risk when women had a very large (20%) mammographic den-
sity change, we removed from the analysis those with a 20% or
greater increase in mammographic density and a 13% increased
breast cancer risk with hormone use persisted (OR ¼ 1.13, 95%
CI¼ 0.77 to 1.65). Further adjustment for mammographic den-
sity change eliminated that association (OR ¼ 0.97, 95% CI¼ 0.63
to 1.51). The attributable fraction comparing a 20% or greater in-
crease to a less than 1% increase in density identified that 17%
of the breast cancer cases were potentially explained by in-
creased breast density after estrogen plus progestin initiation.
Discussion
In this case-control study, nested in the WHI trial, breast cancer
risk increased with increasing mammographic density follow-
ing estrogen plus progestin initiation. For every 1% increase in
mammographic density among those assigned estrogen plus
progestin, breast cancer risk increased 3.4%. Adjustment for
mammographic density change left no residual effect of com-
bined estrogen plus progestin use on breast cancer risk. Our re-
sults suggested that increased mammographic density with
estrogen plus progestin initiation should raise concern and war-
rant consideration of stopping therapy. In the WHI randomized
trial, in addition to increasing breast cancer incidence (2), estro-
gen plus progestin also statistically significantly interfered with
breast cancer detection (28), leading to more advanced stage at
diagnosis (2,29), increased breast cancer mortality (21), and
other adverse health outcomes (30).
These results pertained to postmenopausal women initiat-
ing estrogen plus progestin therapy and not to use of estrogen
alone. This nested study’s strengths included the assessment of
serial mammograms using validated quantitative measures of
density and the WHI strengths of the randomized placebo-
controlled trial design, large participant numbers, comprehen-
sive breast cancer risk assessment, central breast cancer adjudi-
cation, and requirement for annual mammography and clinical
breast exam. Using the average measure of mammographic
density from four readers provided a more conservative esti-
mate of assessing mammographic density where no established
gold standard for assessment exists. Retrospectively collecting
mammograms required participant re-consent, limiting this
study’s numbers. Although we obtained 61% of requested mam-
mograms with differences in recovery by case-control status, no
meaningful differences in mammogram recovery existed be-
tween estrogen plus progestin and placebo-assigned partici-
pants overall, reducing concerns of bias. We conducted an
intent-to-treat analysis based on WHI random assignment. Our
study measure, mammographic density change, would only be
Table 2. Adjusted odds ratios and 95% confidence intervals for breast
cancer associated with continuous measures of baseline mammo-
graphic breast density and change in percent mammographic
density
Analysis categories OR* (95% CI)
Placebo (n¼ 432)
Baseline percent mammographic density† 1.00 (0.98 to 1.02)
Change in percent mammographic density† 1.04 (0.98 to 1.11)
Estrogen plus progestin (n¼475)
Baseline percent mammographic density† 1.03 (1.01 to 1.05)
Change in percent mammographic density† 1.03 (1.01 to 1.06)
*All logistic regression models adjusted for baseline body mass index, age, clini-
cal center, age at first birth, and parity, and the odds ratio is the increase in
breast cancer risk with a 1% increase in mammographic density. These analyses
were mutually adjusted for baseline and change in percent mammographic den-
sity. CI ¼ confidence interval; OR ¼ odds ratio.
†A mean value based on the average of readers 1–4.
Table 3. The adjusted odds ratios and 95% confidence intervals asso-
ciated with change of 1% mammographic breast density from base-
line to one year by treatment group within strata of baseline density
Analysis category No. of cases/controls OR* (95% CI)
Placebo (n¼ 432)
Baseline density, %
<10 48/189 1.08 (0.98 to 1.18)
10–25 16/97 1.01 (0.89 to 1.15)




<10 45/207 1.04 (1.00 to 1.07)
10–25 27/99 1.08 (1.02 to 1.14)
>25 25/72 0.94 (0.87 to 1.01)
*All odds ratio adjusted for age, baseline body mass index, clinical center, age at
first birth, and parity and are the increase in breast cancer risk with a 1% change
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minimally impacted by noncompliance (<10% at year 1). Given
higher noncompliance with years of follow-up, in the WHI the
true effect of mammographic density change on breast cancer
risk was likely underestimated given the noncompliance in
both arms of the study.
This study was not without limitations. The number of cases
detected in the WHI clinical trial before the trial stopped and
our ability to obtain mammograms limited this study’s size.
The number of breast cancer cases in the placebo arm with both
mammograms obtained (n ¼ 77) could have limited detectabil-
ity of statistically significant risk with a 1% increase in baseline
breast density. We found statistically significant and slightly
negative interactions between baseline mammographic density
and treatment arm, and baseline mammographic density and
mammographic density change with respect to breast cancer
risk. Given this negative interaction and as the women who be-
came cases in the estrogen plus progestin arm had higher base-
line density despite random assignment, all analyses controlled
for baseline density. The negative interaction with mammo-
graphic density change suggested that already high breast can-
cer risk in women with high baseline mammographic density
did not increase as much with density change from estrogen
plus progestin use as did risk for women who started with a low
baseline mammographic density. However, this interaction
should be interpreted with caution, as it may have reflected the
limitations in measuring density change among women with
dense breasts.
The current findings support emerging evidence that physi-
ologic responses in breast tissue to hormone-based intervention
may foreshadow subsequent breast cancer risk. For women as-
signed estrogen plus progestin, in the highest 20th percentile of
increased mammographic density, 3.6-fold increased breast
cancer risk was statistically significant. Cuzick and colleagues
(31) reported a breast cancer risk reduction among women with
the greatest mammographic density reduction from a case-
control study nested in the first International Breast Cancer
Intervention Study (IBIS-I), a randomized prevention trial com-
paring tamoxifen with placebo. In women receiving tamoxifen,
the categorical mammographic density reduction was linked
with subsequent breast cancer incidence reduction. However,
analyses adjusting for tamoxifen-associated mammographic
density change were not presented.
Measuring mammographic density at only one time point
for each woman, Boyd and colleagues (32) provided indirect evi-
dence that mammographic density was a biomarker of breast
cancer risk. Combining data from three nested case-control
studies, they found that estrogen plus progestin users who de-
veloped breast cancer had higher mammographic density.
Crandall and colleagues reported on breast tenderness onset in
WHI estrogen plus progestin trial participants (33,34). After one
year, women using estrogen plus progestin compared with
placebo experienced breast tenderness more often (36% vs 12%,
P < .001) and breast cancer risk increased (P ¼ .02) for those tak-
ing estrogen plus progestin who had breast tenderness.
Mammographic breast density was associated with breast ten-
derness, yet adjusting for breast tenderness onset did not re-
move but lowered the estrogen plus progestin breast cancer risk
association (HR ¼ 1.19, 95% CI ¼ 0.94 to 1.76, after adjustment)
(33,35). In contrast, in our study, adjustment for mammographic
density change eliminated the increased risk among estrogen
plus progestin users, suggesting that mammographic density
change better predicted breast cancer risk from estrogen plus
progestin use than did breast tenderness.
In our analyses, after adjustment for mammographic density
change, estrogen plus progestin use no longer increased breast can-
cer risk (OR ¼ 1.00, 95% CI¼ 0.66 to 1.51). Mediation analyses found
no residual direct effect of estrogen plus progestin use on breast
cancer risk after including the indirect mammographic density
change effect. These findings clarify the estrogen plus progestin
use, mammographic density change, and breast cancer risk associ-
ations. In this study, mammographic density change with estrogen
plus progestin use was an intermediate surrogate marker of breast
cancer risk. Based on this study, doctors should evaluate changes
in mammographic density in women who initiate estrogen plus
progestin therapy and discuss the breast cancer risk implications.
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Table 4. Breast cancer risk by quintile of change in percent mammographic density
Analysis categories Q1* Q2 Q3 Q4 Q5
Placebo (n¼ 432)
Cut-points† <-2.77 <-0.51 <0.40 <2.2 2.2
OR (95% CI) 1.00 (ref) 0.94 (0.38 to 2.30) 1.38 (0.54 to 3.48) 0.96 (0.38 to 2.43) 1.20 (0.48 to 2.97)
Estrogenþprogestin (n¼ 475)
Cut-points† <0.64 <4.61 <10.68 <19.32 19.32
OR (95% CI) 1.00 (ref) 1.77 (0.76 to 4.12) 1.04 (0.45 to 2.43) 1.72 (0.74 to 4.02) 3.61 (1.52 to 8.56)
*Q1 is the reference category for comparisons within the treatment arm. All odds ratios adjusted for age, baseline body mass index, clinical center, age at first birth,
and parity. CI ¼ confidence interval; OR ¼ odds ratio.












/jnci/article-abstract/109/9/djx001/3064857 by guest on 19 M
ay 2020
WHI Investigators: Program Office: (National Heart, Lung,
and Blood Institute, Bethesda, MD) Jacques Rossouw, Shari
Ludlam, Dale Burwen, Joan McGowan, Leslie Ford, and Nancy
Geller; Clinical Coordinating Center: (Fred Hutchinson Cancer
Research Center, Seattle, WA) Garnet Anderson, Ross Prentice,
Andrea LaCroix, and Charles Kooperberg; Investigators and
Academic Centers: (Brigham and Women’s Hospital, Harvard
Medical School, Boston, MA) JoAnn E. Manson; (MedStar Health
Research Institute/Howard University, Washington, DC) Barbara
V. Howard; (Stanford Prevention Research Center, Stanford, CA)
Marcia L. Stefanick; (The Ohio State University, Columbus, OH)
Rebecca Jackson; (University of Arizona, Tucson/Phoenix, AZ)
Cynthia A. Thomson; (University at Buffalo, Buffalo, NY) Jean
Wactawski-Wende; (University of Florida, Gainesville/
Jacksonville, FL) Marian Limacher; (University of Iowa, Iowa
City/Davenport, IA) Robert Wallace; (University of Pittsburgh,
Pittsburgh, PA) Lewis Kuller; (Wake Forest University School of
Medicine, Winston-Salem, NC) Sally Shumaker; Women’s
Health Initiative Memory Study: (Wake Forest University School
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